Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 10 | 2022 | 7130 | 1.100 |
Why?
|
| Rubinstein-Taybi Syndrome | 1 | 2022 | 16 | 0.820 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2020 | 124 | 0.780 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 118 | 0.770 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2021 | 27 | 0.750 |
Why?
|
| Sodium Benzoate | 1 | 2020 | 7 | 0.740 |
Why?
|
| Cross Infection | 2 | 2022 | 550 | 0.740 |
Why?
|
| Atovaquone | 1 | 2019 | 8 | 0.710 |
Why?
|
| Hyperammonemia | 1 | 2020 | 68 | 0.700 |
Why?
|
| Phenylbutyrates | 1 | 2020 | 62 | 0.700 |
Why?
|
| Sepsis | 2 | 2022 | 668 | 0.690 |
Why?
|
| Interleukin-10 | 1 | 2022 | 486 | 0.680 |
Why?
|
| Burkitt Lymphoma | 1 | 2022 | 344 | 0.660 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 272 | 0.650 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 268 | 0.620 |
Why?
|
| Brain Diseases | 1 | 2020 | 403 | 0.560 |
Why?
|
| STAT3 Transcription Factor | 3 | 2021 | 1142 | 0.520 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 795 | 0.510 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 1151 | 0.510 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1331 | 0.380 |
Why?
|
| Signal Transduction | 2 | 2019 | 12145 | 0.340 |
Why?
|
| Child | 11 | 2022 | 30357 | 0.340 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 2020 | 44 | 0.340 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 2869 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4458 | 0.300 |
Why?
|
| Immunotherapy | 1 | 2021 | 3518 | 0.280 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 1581 | 0.260 |
Why?
|
| Recurrence | 3 | 2022 | 4889 | 0.210 |
Why?
|
| Haploidy | 1 | 2022 | 44 | 0.200 |
Why?
|
| Chlorhexidine | 1 | 2022 | 87 | 0.200 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 37 | 0.200 |
Why?
|
| CREB-Binding Protein | 1 | 2022 | 93 | 0.200 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 132 | 0.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 760 | 0.190 |
Why?
|
| Fractures, Spontaneous | 1 | 2021 | 85 | 0.190 |
Why?
|
| STAT5 Transcription Factor | 1 | 2021 | 224 | 0.180 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2019 | 78 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2020 | 189 | 0.170 |
Why?
|
| Osteomyelitis | 1 | 2021 | 246 | 0.160 |
Why?
|
| Periosteum | 1 | 2019 | 39 | 0.160 |
Why?
|
| Humans | 19 | 2022 | 270969 | 0.150 |
Why?
|
| Paresis | 1 | 2018 | 54 | 0.150 |
Why?
|
| Interleukin-6 | 1 | 2022 | 1058 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 349 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 1615 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 883 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 952 | 0.140 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 426 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 552 | 0.130 |
Why?
|
| Neoplasms | 1 | 2022 | 15797 | 0.130 |
Why?
|
| Infant | 4 | 2021 | 13889 | 0.130 |
Why?
|
| Rhodium | 1 | 2015 | 7 | 0.130 |
Why?
|
| Bacteremia | 1 | 2022 | 694 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2021 | 16882 | 0.130 |
Why?
|
| Hemophilia B | 1 | 2015 | 14 | 0.130 |
Why?
|
| Naphthalenes | 1 | 2015 | 84 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 1977 | 0.120 |
Why?
|
| Methotrexate | 1 | 2018 | 1023 | 0.120 |
Why?
|
| Genotype | 1 | 2022 | 4015 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1379 | 0.110 |
Why?
|
| Cell Survival | 1 | 2019 | 3064 | 0.110 |
Why?
|
| Prognosis | 2 | 2022 | 22348 | 0.110 |
Why?
|
| Cytokines | 1 | 2022 | 2870 | 0.110 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 502 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 1872 | 0.110 |
Why?
|
| Transcriptome | 1 | 2021 | 1963 | 0.100 |
Why?
|
| Adolescent | 5 | 2021 | 32464 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 1330 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3962 | 0.090 |
Why?
|
| Female | 7 | 2022 | 147624 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14928 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1907 | 0.090 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5810 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 7456 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 597 | 0.090 |
Why?
|
| Apoptosis | 2 | 2019 | 7756 | 0.070 |
Why?
|
| Mutation | 3 | 2022 | 15640 | 0.070 |
Why?
|
| Survival Rate | 1 | 2020 | 12475 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2015 | 1900 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2015 | 1169 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2657 | 0.070 |
Why?
|
| Young Adult | 2 | 2021 | 22268 | 0.060 |
Why?
|
| Adult | 2 | 2022 | 80872 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 10282 | 0.060 |
Why?
|
| Mice | 3 | 2020 | 35455 | 0.060 |
Why?
|
| Male | 6 | 2021 | 127769 | 0.060 |
Why?
|
| Levofloxacin | 1 | 2022 | 58 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 10641 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2021 | 87 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2021 | 136 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 261 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 215 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2021 | 170 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 209 | 0.040 |
Why?
|
| Animals | 3 | 2020 | 61175 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 16327 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 417 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 573 | 0.040 |
Why?
|
| Antidotes | 1 | 2018 | 28 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 697 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 909 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 688 | 0.040 |
Why?
|
| Vidarabine | 1 | 2022 | 1361 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14558 | 0.040 |
Why?
|
| Leucovorin | 1 | 2018 | 340 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 1093 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2019 | 299 | 0.030 |
Why?
|
| Cytarabine | 1 | 2022 | 1994 | 0.030 |
Why?
|
| Factor IX | 1 | 2015 | 27 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 349 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 251 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2021 | 2474 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 887 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 568 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 4357 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 966 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 420 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 5094 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 777 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 750 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 2209 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3002 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5228 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 3119 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 2434 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2496 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 5021 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5298 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 15255 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 2993 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4219 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 6814 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 7333 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 39724 | 0.010 |
Why?
|